WO2002068650A3 - Modified and stabilized gdf propeptides and uses thereof - Google Patents

Modified and stabilized gdf propeptides and uses thereof Download PDF

Info

Publication number
WO2002068650A3
WO2002068650A3 PCT/US2002/003467 US0203467W WO02068650A3 WO 2002068650 A3 WO2002068650 A3 WO 2002068650A3 US 0203467 W US0203467 W US 0203467W WO 02068650 A3 WO02068650 A3 WO 02068650A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
muscle
modified
propeptides
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003467
Other languages
French (fr)
Other versions
WO2002068650B1 (en
WO2002068650A2 (en
Inventor
Neil M Wolfman
Soo Peang Khor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ527286A priority Critical patent/NZ527286A/en
Priority to EP02709366A priority patent/EP1397492B1/en
Priority to HK04104973.9A priority patent/HK1062457B/en
Priority to CA002437218A priority patent/CA2437218A1/en
Priority to BR0207110-0A priority patent/BR0207110A/en
Priority to JP2002568744A priority patent/JP4280071B2/en
Priority to DK02709366T priority patent/DK1397492T3/en
Priority to MXPA03007063A priority patent/MXPA03007063A/en
Priority to AU2002243852A priority patent/AU2002243852B2/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to DE60219006T priority patent/DE60219006T2/en
Publication of WO2002068650A2 publication Critical patent/WO2002068650A2/en
Priority to NO20033456A priority patent/NO333427B1/en
Anticipated expiration legal-status Critical
Publication of WO2002068650A3 publication Critical patent/WO2002068650A3/en
Publication of WO2002068650B1 publication Critical patent/WO2002068650B1/en
Priority to CY20071100719T priority patent/CY1106629T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasteing syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity) and bone degenerative diseases (such as osteoporosis).
PCT/US2002/003467 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof Ceased WO2002068650A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU2002243852A AU2002243852B2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
HK04104973.9A HK1062457B (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
CA002437218A CA2437218A1 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
BR0207110-0A BR0207110A (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
JP2002568744A JP4280071B2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
DK02709366T DK1397492T3 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and their applications
MXPA03007063A MXPA03007063A (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof.
NZ527286A NZ527286A (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
DE60219006T DE60219006T2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and their uses
EP02709366A EP1397492B1 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
NO20033456A NO333427B1 (en) 2001-02-08 2003-08-04 Modified GDF-8 propeptides, process for their preparation and use, nucleic acid molecule encoding modified GDF-8 propeptide, and pharmaceutical composition
CY20071100719T CY1106629T1 (en) 2001-02-08 2007-05-29 MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26750901P 2001-02-08 2001-02-08
US60/267,509 2001-02-08

Publications (3)

Publication Number Publication Date
WO2002068650A2 WO2002068650A2 (en) 2002-09-06
WO2002068650A3 true WO2002068650A3 (en) 2003-08-21
WO2002068650B1 WO2002068650B1 (en) 2004-01-08

Family

ID=23019083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003467 Ceased WO2002068650A2 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof

Country Status (22)

Country Link
US (6) US7202210B2 (en)
EP (1) EP1397492B1 (en)
JP (3) JP4280071B2 (en)
AR (1) AR032567A1 (en)
AT (1) ATE357519T1 (en)
AU (1) AU2002243852B2 (en)
BR (1) BR0207110A (en)
CA (2) CA2674673A1 (en)
CL (1) CL2009000648A1 (en)
CY (1) CY1106629T1 (en)
DE (1) DE60219006T2 (en)
DK (1) DK1397492T3 (en)
ES (1) ES2284828T3 (en)
MX (1) MXPA03007063A (en)
NO (1) NO333427B1 (en)
NZ (2) NZ550297A (en)
PL (2) PL207202B1 (en)
PT (1) PT1397492E (en)
SG (2) SG187989A1 (en)
TW (2) TWI329129B (en)
WO (1) WO2002068650A2 (en)
ZA (2) ZA200508954B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280214B2 (en) 2009-11-05 2019-05-07 Hoffmann-La Roche Inc. Glycosylated repeat-motif-molecule conjugates

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (en) 2002-02-21 2011-07-05 Wyeth Corp gasp1: protein containing folistatin domain
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2008507288A (en) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII receptor polypeptides, methods, and compositions
MX2007000976A (en) * 2004-08-12 2007-04-10 Wyeth Corp Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors.
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US8088508B2 (en) 2005-01-31 2012-01-03 Panasonic Corporation Thermal battery
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
MX2007011400A (en) * 2005-03-23 2007-10-11 Wyeth Corp Detection of gdf-8 modulating agents.
EP1864139A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
BRPI0618947B1 (en) * 2005-11-23 2022-07-19 Acceleron Pharma Inc ACTRIIA POLYPEPTIDE THAT BINDS ACTIVIN, POLYNUCLEOTIDE ISOLATED, POLYNUCLEOTIDE, RECOMBINANT, METHOD FOR PREPARING AN ACTRIIA POLYPEPTIDE THAT BINDS ACTIVIN, PHARMACEUTICAL PREPARATION AND USE OF AN ACTRIIA-FC FUSION PROTEIN TO PROMOTE BONE GROWTH AND INHIBITS BONE RESORPTION
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
JP6047270B2 (en) * 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Methods and means for treating genetic disorders associated with instability of DNA repeats
CA2672758C (en) * 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI584815B (en) * 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 Activin-ActRIIa antagonist and its use for treating or preventing breast cancer
TW201627320A (en) * 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and their uses
MX2009008510A (en) 2007-02-09 2010-01-15 Acceleron Pharma Inc Activin-actriia antagonists and uses for promoting bone growth in cancer patients.
WO2009008727A2 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
JP2010533170A (en) * 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． Molecules for targeting compounds to various selected organs, tissues or tumor cells
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
CA2699936A1 (en) * 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
JP2011510678A (en) * 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Methods and means for treating DNA repeat instability related genetic disorders
EP2303311B1 (en) 2008-05-14 2018-08-01 Agriculture Victoria Services Pty Ltd Angiogenin for use in treating skeletal muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2315602A4 (en) * 2008-06-26 2011-11-02 Acceleron Pharma Inc METHODS FOR ADMINISTERING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
DK3750552T5 (en) 2008-08-14 2024-08-26 Acceleron Pharma Inc GDF TRAPS
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN104829714A (en) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 Antibodies that specifically block the biological activity of a tumor antigen
AU2010204985A1 (en) * 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CN102459595A (en) 2009-04-24 2012-05-16 普罗森那技术公司 Inosine-containing oligonucleotides for the treatment of DMD
MX355042B (en) 2009-06-08 2018-04-02 Acceleon Pharma Inc Methods for increasing thermogenic adipocytes.
CN107267520A (en) 2009-06-12 2017-10-20 阿塞勒隆制药公司 The ACTRIIB FC fusion proteins of truncation
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
EP3260130B1 (en) * 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
ES2658292T3 (en) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses thereof with respect to the induction of utrophin for the treatment of muscular dystrophy
AU2010335039B2 (en) 2009-12-24 2015-03-26 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Molecule for treating an inflammatory disorder
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
EP2768944B2 (en) 2011-10-21 2023-11-22 Pfizer Inc. Addition of iron to improve cell culture
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
JP6254146B2 (en) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Compositions and methods for treating metabolic disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014000042A1 (en) * 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
EP4678239A3 (en) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP6401172B2 (en) 2012-10-24 2018-10-10 セルジーン コーポレイション How to treat anemia
CA2889209C (en) * 2012-10-24 2023-08-22 Celgene Corporation Biomarker for use in treating anemia
RU2678117C2 (en) 2012-11-02 2019-01-23 Селджин Корпорейшн Activin-actrii antagonists and uses thereof for treating bone and other disorders
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014119753A1 (en) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 Myostatin-inhibiting peptide
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
LT3027642T (en) * 2013-07-31 2020-10-12 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
CN104725513A (en) * 2013-12-20 2015-06-24 中国科学院上海生命科学研究院 Fusion protein and its use in multiple sclerosis treatment
CN114699529A (en) 2014-06-13 2022-07-05 阿塞勒隆制药公司 Methods and compositions for treating ulcers
JP6704358B2 (en) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド Compositions and methods of use for treating metabolic disorders
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
CN106687128B (en) 2014-10-31 2022-05-10 Ngm生物制药有限公司 Compositions and methods for treating metabolic disorders
EP3227675B1 (en) 2014-12-03 2023-03-15 Celgene Corporation Activin-actrii antagonists and uses for treating myelodysplastic syndrome
IL293766B2 (en) 2016-01-06 2023-08-01 Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
CN117986363A (en) 2016-03-31 2024-05-07 恩格姆生物制药公司 Binding proteins and methods of use thereof
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024058A2 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Neuronal uses of bmp-11
WO1999045949A2 (en) * 1998-03-09 1999-09-16 Genetics Institute, Inc. Use of follistatin to modulate gdf-8 and bmp-11
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
WO2002009641A2 (en) * 2000-07-27 2002-02-07 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
DK518384A (en) 1984-01-31 1985-07-01 Idaho Res Found VECTOR FOR THE MANUFACTURE OF A GENE PRODUCT IN INSECT CELLS, PROCEDURE FOR ITS MANUFACTURING AND ITS USE
CA1341617C (en) 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
ES8701226A1 (en) 1984-07-06 1986-11-16 Sandoz Ag Lymphokine production and purification.
EP0169016B2 (en) 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5215893A (en) 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
KR900700617A (en) 1988-04-08 1990-08-16 브루스 엠. 에이센 Bone and Cartilage Inducing Compositions
US5071834A (en) 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
ATE162223T1 (en) 1989-03-28 1998-01-15 Genetics Inst OSTEOINDUCTIVE COMPOSITIONS
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5166190A (en) 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
CA2082941A1 (en) 1990-05-16 1991-11-17 Rodney M. Hewick Bone and cartilage inductive proteins
ATE253589T1 (en) 1990-09-26 2003-11-15 Inst Genetics Llc BMP-5 DERIVATIVES
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
DE69226871T3 (en) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A receptor, fusion proteins containing it and their use
US5171579A (en) 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
KR100259827B1 (en) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 Recombinant bone morphogenetic protein heterodimer, composition thereof and method of use
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
EP0716610B1 (en) * 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
DE69534468T2 (en) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine GROWTH DIFFERENTIATION FACTOR 11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5466190A (en) * 1994-07-25 1995-11-14 Deere & Company Precleaner for a cleaning shoe
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
JPH10262688A (en) * 1994-11-30 1998-10-06 Univ Rockefeller Modulators of body weight, corresponding nucleic acids and proteins, and their diagnostic and therapeutic uses
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ATE493141T1 (en) 1996-03-22 2011-01-15 Stryker Corp METHOD FOR IMPROVED FUNCTIONAL RECOVERY OF MOTOR COORDINATION, LANGUAGE OR SENSORY PERCEPTION AFTER CNS TRAUMA OR ISCHEMIA
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
AR008077A1 (en) * 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz A FUSION POLYPEPTIDE OR A SALT OF THE SAME, ITS USE, A PROCESS TO PREPARE THEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND A VECTOR.
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6396201B1 (en) * 1997-08-19 2002-05-28 Miyota Co., Ltd. Piezoelectric vibrator
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
WO1999024618A1 (en) 1997-11-10 1999-05-20 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU782493B2 (en) * 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
EE200200025A (en) 1999-07-20 2003-04-15 Pharmexa A/S A method for down-regulating GDF-8 activity, a method for increasing the muscle mass of an animal, a GDF-8 analog, an immunogenic composition, a nucleic acid fragment, a vector, a transformed cell and a method of making it, a composition of anti-GDF-8 antibodies.
AU2001241817A1 (en) 2000-02-29 2001-09-12 Zymogenetics Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL350983A1 (en) * 2001-11-30 2003-06-02 Advanced Digital Broadcast Ltd Method of scanning a high-frequency signal band and apparatus therefor
BR0307907A2 (en) 2002-02-21 2011-07-05 Wyeth Corp gasp1: protein containing folistatin domain
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
AU2003267246A1 (en) * 2002-09-16 2004-04-30 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003301195B2 (en) 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
EP1864139A2 (en) 2005-03-23 2007-12-12 Wyeth Detection of an immune response to gdf-8 modulating agents
MX2007011400A (en) 2005-03-23 2007-10-11 Wyeth Corp Detection of gdf-8 modulating agents.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024058A2 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Neuronal uses of bmp-11
WO1999045949A2 (en) * 1998-03-09 1999-09-16 Genetics Institute, Inc. Use of follistatin to modulate gdf-8 and bmp-11
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
WO2002009641A2 (en) * 2000-07-27 2002-02-07 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHU X. ET AL.: "Dominant negative myostatin produces hypertrophy without hyperplasia in muscle", FEBS LETTERS, vol. 474, no. 1, 26 May 2000 (2000-05-26), pages 71 - 75, XP004337183, ISSN: 0014-5793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280214B2 (en) 2009-11-05 2019-05-07 Hoffmann-La Roche Inc. Glycosylated repeat-motif-molecule conjugates

Also Published As

Publication number Publication date
NO20033456L (en) 2003-10-06
NO20033456D0 (en) 2003-08-04
US20070149455A1 (en) 2007-06-28
BR0207110A (en) 2005-08-16
EP1397492B1 (en) 2007-03-21
DE60219006T2 (en) 2007-12-13
SG187989A1 (en) 2013-03-28
EP1397492A2 (en) 2004-03-17
JP4280071B2 (en) 2009-06-17
PL212078B1 (en) 2012-08-31
HK1062457A1 (en) 2004-11-05
US20030104406A1 (en) 2003-06-05
PT1397492E (en) 2007-06-15
US20070238683A1 (en) 2007-10-11
US20120252884A1 (en) 2012-10-04
DE60219006D1 (en) 2007-05-03
WO2002068650B1 (en) 2004-01-08
ATE357519T1 (en) 2007-04-15
JP2006001938A (en) 2006-01-05
ES2284828T3 (en) 2007-11-16
NZ527286A (en) 2006-11-30
CL2009000648A1 (en) 2009-06-12
AR032567A1 (en) 2003-11-12
US20140228289A1 (en) 2014-08-14
US7560441B2 (en) 2009-07-14
JP2009091366A (en) 2009-04-30
TW200526779A (en) 2005-08-16
ZA200508954B (en) 2006-07-26
ZA200306064B (en) 2006-02-22
MXPA03007063A (en) 2004-10-15
JP5013618B2 (en) 2012-08-29
SG165982A1 (en) 2010-11-29
DK1397492T3 (en) 2007-07-09
US8222384B2 (en) 2012-07-17
JP2005507637A (en) 2005-03-24
PL372888A1 (en) 2005-08-08
TWI329129B (en) 2010-08-21
PL207202B1 (en) 2010-11-30
US20100305194A1 (en) 2010-12-02
US8710025B2 (en) 2014-04-29
CY1106629T1 (en) 2012-01-25
US7202210B2 (en) 2007-04-10
CA2437218A1 (en) 2002-09-06
NO333427B1 (en) 2013-06-03
US7737116B2 (en) 2010-06-15
AU2002243852B2 (en) 2007-08-16
NZ550297A (en) 2008-04-30
CA2674673A1 (en) 2002-09-06
WO2002068650A2 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
SG165982A1 (en) Modified and stabilized bmp-11 propeptides and uses thereof
Hunter et al. Fifth metacarpal fractures in a compensation clinic population: a report on one hundred and thirty-three cases
AU2003273967A1 (en) Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
AP2002002634A0 (en) Malonamic Acids And Derivatives Thereof As Thyroid Receptor Ligands.
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2006081230A3 (en) 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
WO2002077155A3 (en) Keratinocyte growth factor-2
EP1273269A3 (en) Implantable screw for stabilising an articulated joint or a bone fracture
WO2005019256A3 (en) Muteins of tear lipocalin
WO2004099192A3 (en) Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
WO2004039948A3 (en) Actriib fusion polypeptides and uses therefor
CA2265508A1 (en) Bone morphogenetic protein-16 (bmp-16) compositions
JP2005507637A5 (en)
WO2003018752A3 (en) An organotypic intestinal culture and methods of use thereof
WO2002047685A3 (en) Nmda receptor agonist pharmaceutical compositions
WO2003099992A3 (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
CN101268098A (en) Liquid formulations of pegylated growth hormone
WO2001000566A3 (en) Substituted phenoxyacetic acids
WO2000003610A8 (en) Method for producing an iodinated food product
WO2002070546A3 (en) Modified derivatives of cck-8
EP1790726A3 (en) Modified and stabilized GDF propeptides and uses thereof
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2437218

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 527286

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/06064

Country of ref document: ZA

Ref document number: 2002568744

Country of ref document: JP

Ref document number: 200306064

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007063

Country of ref document: MX

Ref document number: 372888

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2002243852

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002709366

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

B Later publication of amended claims

Effective date: 20030423

WWP Wipo information: published in national office

Ref document number: 2002709366

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002709366

Country of ref document: EP